Welichem Filed Annual Report Ended May 31, 2009

BURNABY, BC, Sept. 29 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that the Company filed its annual audited financials and MD & A. The net loss for the year ended May 31, 2009 was $2,701,954 (2008 - restated $2,503,756) and 16 cents per share (2008 - 34 cents per share). The loss per share and weighted average number of common shares outstanding were recalculated retroactively to reflect the ten-to-one share consolidation implemented on September 3, 2009.

Detailed information is available on SEDAR website (www.sedar.com).

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of inflammatory diseases and cancer.

    
    ON BEHALF OF THE BOARD

    Xiangdong Tan
    Chairman
    

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

%SEDAR: 00021386E

SOURCE Welichem Biotech Inc.

For further information: For further information: Genhui Chen, Tel.: (604) 432-1703, Email: gchen@welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890